Scope Biosciences
Scope Biosciences is a Dutch biotech company specializing in CRISPR-Cas based molecular diagnostics. Founded in 2020 as a spin-off of Wageningen University & Research, the company develops highly accurate, on-site diagnostic solutions for healthcare and agriculture, leveraging innovative CRISPR-Cas technology to enable rapid, reliable testing outside traditional laboratories. Their mission is to revolutionize diagnostics with a focus on sustainability, precision, and accessibility.
Industries
Nr. of Employees
small (1-50)
Scope Biosciences
Products
Diagnostic assay — ToBRFV (Tomato)
CRISPR-Cas based nucleic acid assay for detection of Tomato brown rugose fruit virus in tomato samples, with user manuals, validation sheet, SDS and instrument protocol files.
Diagnostic assay — ToMV (Tomato / Bell pepper)
CRISPR-Cas based assay for detection of Tomato mosaic virus in tomato and bell pepper, including user manuals, validation documentation, SDS and device protocols.
Diagnostic assays — assorted plant pathogens (CGMMV, A. radicina, A. dauci, A. citrulli, ToFBV)
A catalogue of CRISPR-Cas based assays for multiple crop pathogens (cucurbit viruses, Agrobacterium and Alternaria species, etc.) supplied with validation sheets, SDS and device protocols.
Diagnostic assay — ToBRFV (Tomato)
CRISPR-Cas based nucleic acid assay for detection of Tomato brown rugose fruit virus in tomato samples, with user manuals, validation sheet, SDS and instrument protocol files.
Diagnostic assay — ToMV (Tomato / Bell pepper)
CRISPR-Cas based assay for detection of Tomato mosaic virus in tomato and bell pepper, including user manuals, validation documentation, SDS and device protocols.
Diagnostic assays — assorted plant pathogens (CGMMV, A. radicina, A. dauci, A. citrulli, ToFBV)
A catalogue of CRISPR-Cas based assays for multiple crop pathogens (cucurbit viruses, Agrobacterium and Alternaria species, etc.) supplied with validation sheets, SDS and device protocols.
Services
Collaborative development of molecular diagnostic assays for agricultural and clinical targets, including partner co-development for transplant diagnostics.
Preparation of validation sheets, user manuals, safety data sheets and instrument protocols to support assay deployment and regulatory submission needs.
Guidance on implementing on-site, rapid diagnostic workflows including sample preparation, one-pot reactions, and portable instrument integration.
Collaborative development of molecular diagnostic assays for agricultural and clinical targets, including partner co-development for transplant diagnostics.
Preparation of validation sheets, user manuals, safety data sheets and instrument protocols to support assay deployment and regulatory submission needs.
Guidance on implementing on-site, rapid diagnostic workflows including sample preparation, one-pot reactions, and portable instrument integration.
Expertise Areas
- Point-of-care molecular diagnostics
- CRISPR-based assay design and engineering
- Isothermal amplification workflows (LAMP integration)
- Agricultural pathogen diagnostics and genotyping
Key Technologies
- Type III CRISPR-Cas detection
- Isothermal LAMP amplification
- One-pot reaction chemistry
- Real-time nucleic acid detection
News & Updates
Scope Biosciences participated in the EIT Health Bootcamp Validation Lab at YES!Delft, a two-month intensive validation program involving workshops and expert meetings across Europe.
The company moved into its own laboratory at Wageningen Campus, expanding its capacity for research and development.
Publication on their Type III CRISPR Diagnostic by Jurre Steens et al. in Nature Communications, highlighting advancements in their diagnostic platform.
Scope Biosciences completed a three-month EIT Health Medtech Validation Lab, validating their market approach in multiple European locations.
The company received a €2.5 million grant to develop their scope _Dx_ platform for point-of-care diagnostics, emphasizing accuracy and ease of use.
A partnership with GenDx to develop diagnostics for transplant applications, leveraging CRISPR-Cas technology.
Scope Biosciences participated in the EIT Health Bootcamp Validation Lab at YES!Delft, a two-month intensive validation program involving workshops and expert meetings across Europe.
The company moved into its own laboratory at Wageningen Campus, expanding its capacity for research and development.
Publication on their Type III CRISPR Diagnostic by Jurre Steens et al. in Nature Communications, highlighting advancements in their diagnostic platform.
Scope Biosciences completed a three-month EIT Health Medtech Validation Lab, validating their market approach in multiple European locations.
The company received a €2.5 million grant to develop their scope _Dx_ platform for point-of-care diagnostics, emphasizing accuracy and ease of use.
A partnership with GenDx to develop diagnostics for transplant applications, leveraging CRISPR-Cas technology.